anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention is the application of resina ferulae volatile oil in preparing an anti-cancer preparation, relates to pharmaceutical uses of resina ferulae volatile oil of Chinese medicine and resina ferulae volatile oil abroad, and aims to provide a new use of the resina ferulae volatile oil. The resina ferulae volatile oil of the invention is used for preparing an anti-cancer preparation. The anti-cancer preparation can be preparations for injection, capsules, pills, tablets, granules, powders, oral liquid or other dosage forms. The resina ferulae volatile oil mainly contains: alfa-pinene, alfa-terpinenes, terpine 4-alcohol, D fenchyl alcohol, pinocarveol, 2-borneol, di-sec-butyl disulphide, sec-butyl- antiform-1-butenyl disulphide, sec-butyl- propenyl disulphide, dimethyl disulphide, dimethyl tersulfide, N.N-dimethyl thioformamide, propenyl-butyl-disulphide. The resina ferulae volatile oil is extracted from the resina ferulae by adopting the common extraction method. The resina ferulae can be oleo-gum-resin of Xinjiang resina ferulae or Fukang resina ferulae, as well as oleo-gum-resin of resina ferulae from Iran, Afghanistan, Sri Lanka, etc. The anti-cancer preparation prepared from the resina ferulae volatile oil is suitable for treating patients suffering from cancers.
Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals for synthetic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of the function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an eryhropoietin. 32 claims, 9 figures
Provided in the present application are a new lipid compound, a lipid nanoparticle containing same and the use thereof in the targeted delivery of a drug. Specifically, provided in the present application are a compound of general formula I, or a pharmaceutically acceptable salt, a prodrug or a stereoisomer thereof. Further provided in the present application is a lipid nanoparticle, which contains a compound of general formula I or a pharmaceutically acceptable salt, a prodrug or a stereoisomer thereof. Furthermore, the lipid nanoparticle may also contain a cationic lipid. In addition, the lipid nanoparticle may also contain an auxiliary lipid. The composition containing the compound, or the pharmaceutically acceptable salt, the prodrug or the stereoisomer thereof or the lipid nanoparticle can achieve the targeted organ delivery function of a therapeutic agent/prophylactic agent.
The invention discloses a traditional Chinese medicine preparation for treating rheumatic arthritis and a preparation method thereof, and belongs to the field of traditional Chinese medicine. The effective constituent of the traditional Chinese medicine preparation is prepared from, rhynchosia volubilis, beefwood-like clubmoss herb, chinaroot greenbrier, herb of Yunnan Ainsliaea, corkleaf snowbell leaves or roots, leaves of Chinese maple, the root of David currant, camphorwood, garden balsam stems, common dysosmatis rhizomes and roots, white mustard seeds, notopterygium roots, common cissampelos herb, herba aristolochiae, needle juniper and herb of style pachysandra. The selected medicines are appropriate in compatibility and bring out the best in one another. The traditional Chinese medicine preparation has the effects of dispelling wind and eliminating dampness, relaxing the muscles and stimulating the blood circulation, eliminating cold to stop pain, warming the middle warmer and regulating qi, promoting blood circulation to arrest pain and the like. The medicines are cooperated to directly reach the diseased region. The traditional Chinese medicine preparation has the advantages of becoming effective rapidly, being high in cure rate, having no toxic or side effect and being safe and convenient to take for treating limb or trunk numbness, wrist joint nodular protrusions, persistent back pain accompanied by morning stiffness, joint local pricking, morning stiffness, spine and limb malformation, joint pain, joint painful swelling and other symptoms caused by rheumatic arthritis, is low in price and easy to prepare and can be widely applicable to clinic treatment on rheumatic arthritis.
The bioactivities of two commercially available probiotics and one chemical disinfectant were tested against strains of Vibrio parahaemolyticus (VPAHPND) and V. harveyi. This study aimed to determine shrimp pathogenic Vibrios' in vitro and in vivo sensitivities to commercial probiotics and a chemical disinfectant. The probiotics and disinfectant were tested first in vitro, followed by the in vivo trials. Results showed that upon administration of probiotics either through diet or adding into the tank water, the survivability of shrimp was increased during challenge with VPAHPND and V. harveyi. Also, the disinfectant was tested against the same pathogens and showed positive bactericidal effects at 2500 ppm and 5000 ppm. The present findings suggest that adding probiotics to the rearing water or the shrimp feeds effectively prevents infection by lowering the load of pathogenic bacteria. In comparison, the effectiveness of the disinfectant (PUR) depends on its appropriate concentration and timing of application. It is not only limited to rearing water but is also applicable for decontaminating pond liners, tanks, and other paraphernalia.
The invention relates to a solid Δ9-THC composition containing Δ9-THC and a powder former and having a molar ratio of Δ9-THC to powder former to form a flowable Δ9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, β-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid Δ9-THC composition of the invention. The Δ9-THC may be synthetic Δ9-THC or may be extracted Δ9-THC. The invention provides pharmaceutical or nutraceutical composition containing a solid Δ9-THC composition of the invention and a pharmaceutically- or nutraceutically-acceptable carrier where Δ9-THC is present in a pharmaceutically or nutraceutically effective amount. The invention also provides methods of treating a disease, disorder, or condition by administering to a patient in need thereof a therapeutically effective amount of a solid Δ9-THC composition. A solid Δ9-THC composition of the invention may also be incorporated into food and beverage products.
Early career educators in the intervention condition will be asked to complete a 5-hour e-learning course over a two week timeframe. The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
Residential care services are under increasing pressure to lower service provision costs while maintaining quality of care. Using a translog cost function, this paper examines the relationship between cost, quality and output in England's learning disability (LD) residential care sector. It finds genuine but diminishing economies of scale in LD residential care services vis-à-vis output (i.e., care weeks). However, some variation exists: higher-quality LD residential care homes appear to have larger economies of scale than lower-quality ones. Supplementary regression analysis, examining quality-size, further finds quality (a) is negatively associated with LD care homes of six or fewer beds; (b) shows no association with homes of more than six beds. These findings enhance residential care literature and raise the possibility that, by promoting the establishment of larger high-quality care homes, cost savings may be achieved without sacrificing quality.
An object of the present invention is to clarify the novel property of lipoteichoic acid derived from the lactic acid bacteria of the genus Apilactobacillus, and provide new uses based on this. The intestinal immune activating agent, IgA production promoter and gene expression promoter of the present invention contain lipoteichoic acid derived from the lactic acid bacteria of the genus Apilactobacillus as an active ingredient. The lactic acid bacteria of the genus Apilactobacillus are the lactic acid bacteria of Apilactobacillus kosoi, Apilactobacillus kunkeei, or Apilactobacillus apinorum. The lactic acid bacteria of the genus Apilactobacillus are Apilactobacillus kosoi strain 10H, Apilactobacillus kunkeei strain JCM16173, or Apilactobacillus apinorum strain JCM30765. The intestinal immunity activating agent is in the form of a food, a medicine, a feed, or an active ingredient composition to be mixed therein. The IgA production promoter is in the form of a food, a medicine, a feed, or an active ingredient composition to be mixed therein. The gene expression promoter contains lipoteichoic acid derived from the lactic acid bacteria of the genus Apiractobacillus as an active ingredient and promotes the expression of at least one factor among IL-6, IL-10, and retinal dehydrogenase 2 (RALDH2) in dendritic cells, wherein the lactic acid bacteria of the genus Apilactobacillus is Apilactobacillus kosoi strain 10H. The gene expression promoter is in the form of a food, a medicine, a feed, or an active ingredient composition to be mixed therein. A use of lipoteichoic acid derived from the lactic acid bacteria of the genus Apilactobacillus is to manufacture a food, a medicine, a feed, or an active ingredient composition to be mixed therein for stimulating intestinal immunity in humans or non-human animals.
Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
OBJECTIVE: Several studies have described disparities between male and female patients following spine surgery, but no pooled analyses have performed a robust review characterizing differences in postoperative outcomes based on gender. The purpose of this study was to broadly assess the effects of gender on postoperative outcomes following elective spine surgery.
METHODS: Between November 2022 and March 2023, PubMed, MEDLINE, ERIC, and Embase were queried using artificial intelligence-assisted software for relevant cohort studies. Cohort studies with a minimum sample of 100 patients conducted in the United States since 2010 were eligible. Studies related to trauma, tumors, infections, and spinal cord pathology were excluded. Independent extraction by multiple reviewers was performed using Nested Knowledge software. A fixed- or random-effects model was used if heterogeneity among included studies in a meta-analysis was < 50% or ≥ 50%, respectively. Risk of bias was assessed independently by multiple reviewers using the Newcastle-Ottawa Scale. Pooled effect sizes were calculated for readmission, nonroutine discharge (NRD), length of stay (LOS), extended LOS, reoperation, mortality, all medical complications (individual analyses for cardiovascular, deep venous thrombosis/pulmonary embolism, genitourinary, neurological, respiratory, and systemic infection complications), and wound-related complications. For each outcome, two subanalyses were performed with studies that used either center-based (single- or multi-institution) or high-volume (national or state-wide) databases.
RESULTS: Across 124 included studies, male patients had an increased incidence of mortality (OR 0.54, p < 0.0001) and all medical complications (OR 0.80, p = 0.0114), specifically cardiovascular (OR 0.68, p < 0.0001) and respiratory (OR 0.76, p = 0.0008) complications. Female patients were more likely to experience a wound-related surgical complication (OR 1.16, p = 0.0183). These findings persisted in the high-volume database subanalyses. Only center-based subanalyses showed that female patients were at greater odds of experiencing an NRD (OR 1.18, p = 0.0476), longer LOS (SMD 0.23, p = 0.0036), and extended LOS (OR 1.28, p < 0.0001).
CONCLUSIONS: Males are more likely to experience death and medical complications, whereas females were more likely to face wound-related surgical complications. At the institution level, females more often experience NRD and longer hospital stays. These findings may better inform preoperative expectation management and provide more detailed postoperative risk assessments based on the patient's gender.
NEW MATERIAL:2,2,4-Trimethyl-1-phenyl-3-pentanol. USE:Useful as a component for perfume composition, having a woody or grapefruit-like fragrance, being blended with any of other various perfume bases and widely usable for perfume, soap, shampoo, rinse, detergent and cosmetic requiring fragrance. PREPARATION:For example, carbonyl group of 2,2,4-trimethyl-1-phenyl-3- pentanone is reduced to give the aimed novel compound. The reduction is carried out by hydrogenating reaction using a metallic catalyst such as a metal hydride, e.g. lithium aluminum hydride or Cu-Cr catalyst. The starting raw material is synthesized by reacting a benzyl halide with diisopropyl ketone in the presence of a base.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to purulent surgery, and can be used in treatment of patients with purulent wounds of soft tissues. For this purpose antibacterial and immune therapy are carried out. Immunotherapy is performed in the following way. Blood is sampled from patient, by plasmapheresis leukocyte cell mass is obtained from it and cultivated with 1 000 000 Units of interleukin -2 and 200 ml of NaCl 0.9% solution for 60 min at temperature 37C, with further centrifugation. After that, obtained complex of cytokins is introduced uniformly subcutaneously symmetrically at distance 1.0 cm from wound edges until infiltration bank in volume 10-80 ml with 10 ml of solution per each 5 cm of wound length is created. Introduction is performed on the 1-st, 3-rd and 5-th day of post-operative period. ^ EFFECT: method makes it possible to increase efficiency of said pathology treatment due to local enhancement of non-specific immune response in region of infection focus. ^ 1 ex
CLLU1, a disease-specific gene associated with chronic lymphoid leukemia (CLL), is located on chromosome 12q22. Previous studies considered CLLU1 to be a non-coding RNA; however, recent research has discovered that its coding sequence region possesses the potential to encode a short peptide similar to interleukin-4. Remarkably, abnormally elevated expression of CLLU1 has only been detected in chronic lymphoid leukemia among all hematological cancers. High CLLU1 expression often indicates more malignant pathological features and an unfavorable prognosis for patients. Importantly, the expression level of CLLU1 remains unaffected by the passage of time or therapeutic interventions, thus rendering it a novel prognostic marker. This article provides a comprehensive summary of relevant research findings on CLLU1 in the context of CLL prognosis and clinical applications, aiming to guide subsequent theoretical and clinical investigations in this field.
PURPOSE: Practicing speech-language pathologists (SLPs) reveal a perceived lack of preparedness to deliver augmentative and alternative communication (AAC) services. This is concerning because it is indicative of inadequate graduate training in AAC. The purpose of this clinical focus article was to present a collaborative model of clinical education for AAC preservice training. This clinical focus article will provide recommendations to support practicing SLPs in the provision of effective clinical instruction for preservice clinicians working with individuals with complex communication needs who require AAC.
METHOD: There is an urgent need for improved training for clinical educators providing instruction in AAC. In this clinical focus article, a literature review of the existing evidence regarding best practices in clinical education and AAC training for SLPs was completed to explore current theoretical and practical approaches. The evidence was utilized to create a collaborative model of recommended clinical education in AAC.
RESULTS: There is limited guidance for clinical educators when it comes to training preservice clinicians. This clinical focus article provides recommendations for AAC training of preservice SLPs by clinical educators in the field of speech-language pathology.
CONCLUSIONS: The collaborative model proposed in this clinical focus article delivers a roadmap to guide practicing SLPs in the development of AAC clinical competence of preservice clinicians. Future research is needed to evaluate the effectiveness of the model.
Endotoxemia is a systemic inflammatory condition caused by lipopolysaccharide (LPS) stimulation, which produces inflammatory cytokines. Fuzapladib (FZP) inhibits the activation of adhesion molecules found on the surface of inflammatory cells, mitigating inflammation. In this study, we evaluated the therapeutic effects of fuzapladib on inflammatory cytokines and cardio-respiratory function using an LPS-induced endotoxemic porcine model. Fifteen pigs were separated into three groups: low-FZP (n=5), high-FZP (n=5), and control (n=5). Pigs were administered LPS under general anesthesia, and complete blood cell count, blood biochemistry, inflammatory cytokines, and cardio-respiratory function were evaluated. Statistical analysis was performed using a linear mixed-effects model and the Steel-Dwass test, with a significance threshold of P<0.05. During the 4 hr experimental period, one pig in the control group and two pigs in the low-FZP group died due to hypoxemia and hypotension. In the early acute changes following LPS administration, the high-FZP group maintained significantly higher arterial oxygen partial pressure and normal blood pressure compared to the control group. Although interleukin-6 levels increased in all groups during the experiment, they were significantly lower in the high-FZP group compared to the control group. Other parameters showed no clinically significant differences. In conclusion, while high-dose fuzapladib did not reduce organ damage in the porcine endotoxemia model, it suppressed interleukin-6 production, delayed the progression of deterioration, and contributed to a reduction in mortality during the observation period.
INTRODUCTION: The Shape Trail Test (STT) was developed based upon the Trail Making Test, as a culture-neutral test for measuring processing speed and mental flexibility. This study aims to evaluate the accuracy and validity of this five-minute test for differentiating individuals with normal cognition (NC), subjective memory impairment (SMI), and mild cognitive impairment (MCI).
METHOD: The study included 210 participants aged 50-80 years, with 70 participants in each group matched for age, education, and gender.
RESULTS: No significant difference in STT measures was found between the NC and SMI groups. In contrast, both the NC and SMI groups exhibited significantly better performance (shorter completion time in STT-A and STT-B and fewer STT-B errors) than the MCI group. No significant group differences were found in STT-A errors. Stepwise regression analysis identified three significant predictors for classifying the MCI group from the NC and/or SMI groups, including the STT-B completion time, the STT-A errors, and the interaction between STT-B completion time and STT-B errors. The composite score of these three predictors demonstrated good discriminatory power for classifying the MCI group from the other groups, with area under the curves (AUCs) of 0.76 - 0.79 (p < 0.001), sensitivities of 78.6% - 80%, and specificities of 60% - 61.4%. However, none of the STT measures or their interactions were significant predictors for differentiating the SMI group from the NC group. Besides, the STT measures were significantly correlated with age, education, and executive function measures.
DISCUSSION: The STT could be a culture- and language-free, reliable test for assessing executive function and a sensitive test for predicting MCI.
BACKGROUND: Chronic pain is a common, complex, and challenging condition, for which specialised healthcare is required. We investigated the relationship between multisite chronic pain (MCP) and different disease traits identify safe biomarker interventions that can prevent MCP.
METHODS: Univariable and multivariable Mendelian randomisation (MR) analysis were conducted to investigate associations between MCP and 36 common diseases in the UK Biobank. Subsequently, we estimated the potential effect of expression of 4774 proteins on MCP utilising existing plasma protein quantitative trait locus data. For the significant biomarkers, we performed phenome-wide MR (Phe-MR) with 1658 outcomes to predict potential safety profiles linked to biomarker intervention.
RESULTS: Multisite chronic pain had a substantial impact on psychiatric and neurodevelopmental traits (major depression and attention deficit hyperactivity disorder), cardiovascular diseases (myocardial infarction, coronary artery disease, and heart failure), respiratory outcomes (asthma, chronic obstructive pulmonary disease, and sleep apnoea), arthropathies, type 2 diabetes mellitus, and cholelithiasis. Higher genetically predicted levels of S100A6, DOCK9, ferritin, and ferritin light chain were associated with a risk of MCP, whereas PTN9 and NEUG were linked to decreased MCP risk. Phe-MR results suggested that genetic inhibition of DOCK9 increased the risk of 21 types of disease, whereas the other biomarker interventions were relatively safe.
CONCLUSIONS: We established that MCP has an effect on health conditions covering various physiological systems and identified six novel biomarkers for intervention. In particular, S100A6, PTN9, NEUG, and ferritin light chain represent promising targets for MCP prevention, as no significant side-effects were predicted in our study.